Nanoform launches technology for biologics and sets new near-term business target for 2021 - Seite 2

Christian Jones, Nanoform CCO: "It is rare for any company to bring to market two groundbreaking platform technologies that could open up significant opportunities for the global pharma industry. I am delighted we are introducing this early development nanoparticle technology in the field of biologics as there are so many areas where nanoparticles can add value in this hugely promising but significantly challenging space. We look forward to exploring the potential advantages with our Pharma and Biotech partners in the hope we can together make better medicines for patients."

Telephone conference for analysts, investors, and media:

In connection with this release and Nanoform's Q3 report release (Nov 27^th at 08.00 a.m. Helsinki time) Nanoform will hold a conference call and online presentation today Friday November 27^th at 15.00 p.m. Helsinki time (14.00 p.m. Stockholm time). Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CTO Niklas Sandler, CCO Christian Jones and CBO Gonçalo Andrade. The presentation will be delivered in English.

The presentation will be broadcast live as a webcast available at: https://financialhearings.com/event/13383

Teleconference dial-in numbers:

Finland: [phone]

Sweden: [phone]

United Kingdom: [phone]

United States: [phone]

For further information, please contact:

Prof. Edward Hæggström, CEO
[e-mail] / [phone]

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations
[e-mail] / [phone]

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on November 27th, 2020 at 07:50 a.m. Finnish time.

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, [phone]. For more information please visit http://www.nanoform.com